Literature DB >> 30994228

Histopathological diagnosis of ulcerative colitis-associated neoplasia.

Hiroshi Kawachi1.   

Abstract

In patients with ulcerative colitis, tumor development occurs with an increase in the duration of the disease. Such lesions, known as ulcerative colitis-associated neoplasia (UCAN), histologically show a broad variety of findings such as low-grade dysplasia, high-grade dysplasia, and invasive carcinoma. For pathologists, however, the histopathological diagnosis of UCAN is occasionally difficult. Problems in pathological diagnosis can be summarized into the following three categories: (i) difficulty in discriminating UCAN from non-neoplastic inflammatory change; (ii) difficulty in discriminating UCAN from sporadic epithelial neoplasm; and (iii) difficulty in histological grading of UCAN. For most lesions, pathologists can make conclusive histological diagnoses without any problems. However, pathologists occasionally face diagnostic difficulties, especially in cases of lesions with borderline or indefinite histology and, therefore, at least two experienced gastrointestinal pathologists are needed to confirm the diagnosis. Hence, a confirmation is usually preferable for the estimation of tumor depth and lymphovascular invasion in digestive tract cancers as well as in UCAN. Immunohistochemistry for p53 and Ki-67 (MIB-1) is occasionally useful as an ancillary tool. Since UCAN has distinct characteristics compared to sporadic epithelial neoplasia, its treatment strategy should be carefully discussed by a multidisciplinary team, especially for cases of lesions with indefinite histology. At present, although surgical intervention such as total colectomy is the most promising procedure for UCAN, recent advances in endoscopic diagnosis and therapy are expected to improve future treatment strategy.
© 2019 Japan Gastroenterological Endoscopy Society.

Entities:  

Keywords:  Histopathological diagnosis; colorectal cancer; dysplasia; neoplasia; ulcerative colitis

Mesh:

Year:  2019        PMID: 30994228     DOI: 10.1111/den.13387

Source DB:  PubMed          Journal:  Dig Endosc        ISSN: 0915-5635            Impact factor:   7.559


  5 in total

1.  The Origin of Epithelium with Low-Grade Atypia in Early Gastric Cancer.

Authors:  Hiroaki Yamada; Hiroaki Kaneko; Hirofumi Kuwashima; Makoto Sugimori; Sho Tsuyuki; Katsuyuki Sanga; Kuniyasu Irie; Tomohiko Sasaki; Masaaki Kondo; Akio Miyake; Shin Maeda
Journal:  Digestion       Date:  2022-02-16       Impact factor: 3.672

2.  Efficacy of resveratrol for the treatment in patients with ulcerative colitis: Study Protocol.

Authors:  Yan-Hui Chen; Yi Xiang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 3.  Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review.

Authors:  Elisa Marabotto; Stefano Kayali; Silvia Buccilli; Francesca Levo; Giorgia Bodini; Edoardo G Giannini; Vincenzo Savarino; Edoardo Vincenzo Savarino
Journal:  Cancers (Basel)       Date:  2022-08-31       Impact factor: 6.575

4.  miR‑31 promotes tumorigenesis in ulcerative colitis‑associated neoplasia via downregulation of SATB2.

Authors:  Yan Song; Kui Jiang; Bang-Mao Wang; Wen-Tian Liu; Rui Lin
Journal:  Mol Med Rep       Date:  2020-10-08       Impact factor: 2.952

5.  Treatment outcomes of endoscopic submucosal dissection and surgery for colorectal neoplasms in patients with ulcerative colitis.

Authors:  Kengo Kasuga; Masayoshi Yamada; Dai Shida; Teppei Tagawa; Hiroyuki Takamaru; Masau Sekiguchi; Taku Sakamoto; Toshio Uraoka; Shigeki Sekine; Yukihide Kanemitsu; Yutaka Saito
Journal:  United European Gastroenterol J       Date:  2021-07-07       Impact factor: 4.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.